home / stock / cing / cing news


CING News and Press, Cingulate Inc. From 05/12/23

Stock Information

Company Name: Cingulate Inc.
Stock Symbol: CING
Market: NASDAQ
Website: cingulate.com

Menu

CING CING Quote CING Short CING News CING Articles CING Message Board
Get CING Alerts

News, Short Squeeze, Breakout and More Instantly...

CING - Cingulate, Indegene to Participate in Benzinga All Live Access Event

KANSAS CITY, Kan., May 12, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, toda...

CING - Cingulate GAAP EPS of -$0.35 misses by $0.01

2023-05-10 17:49:49 ET Cingulate press release ( NASDAQ: CING ): Q1 GAAP EPS of -$0.35 misses by $0.01 . Cash Position: As of March 31, 2023, Cingulate had $1.7 million in cash and cash equivalents. For further details see: Cingulate GAAP EPS of -$0.35 misses...

CING - Cingulate Inc. Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update

Additional $3 Million of Financing Proprietary PTR™ Manufacturing Processes Successfully Transferred to Societal CDMO Joint Commercialization Agreement for Lead ADHD Candidate CTx-1301 KANSAS CITY, Kan., May 10, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: C...

CING - Cingulate Announces Successful Transfer of CTx-1301 (dexmethylphenidate) Proprietary PTR(TM) Manufacturing Processes to Societal CDMO

KANSAS CITY, Kan., May 03, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) , a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutic...

CING - Cingulate Completes First Cohort of Phase 3 Adult Onset and Duration Trial of CTx-1301 (dexmethylphenidate) for ADHD

Trial On Track for 3Q 2023 Results Pivotal Phase 3 Trial in Pediatric/Adolescent Patients Planned to Begin Mid-2023 KANSAS CITY, Kan., April 04, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) , a biopharmaceutical company utilizing its proprietary Precision Tim...

CING - AU, MVST and PALI are among pre market gainers

2023-03-30 08:44:07 ET SCYNEXIS ( SCYX ) +93% jumps 92% on licensing deal with GSK for anti-fungal agent. Freight Technologies ( FRGT ) +23% warded Whirlpool Contract. Cazoo Group ( CZOO ) +19% FY earnings call release Altus Power ( AMPS ) +...

CING - United Airlines, GitLab, TAL Education among premarket losers' pack

2023-03-14 08:34:23 ET GitLab ( GTLB ) -30% on Q4 earnings release . Cingulate ( CING ) -11% . 9 Meters Biopharma ( NMTR ) -9% after proposes to raise $5M in stock offering . BigBear.ai ( BBAI ) -9% on Q4 earnings release . B...

CING - HUT, NMTR and BYSI among mid-day movers

2023-03-13 12:54:16 ET Gainers: Provention ( PRVB ) +258% . Euda Health ( EUDA ) +41% . Calliditas ( CALT ) +31% . Cipher Mining ( CIFR ) +29% . Caleminder ( CMND ) +26% . Bakkt ( BKKT ) +26% . Hut 8 Mining ( HU...

CING - Provention, Caleminder top healthcare gainers; Cingulate, iCAD among losers

2023-03-13 10:02:38 ET Gainers: Provention Bio PRVB +248% . Caleminder ( CMND ) +38% . Calliditas Therapeutics ( CALT ) +32% . Euda Health ( EUDA ) +22% . Seagen  ( SGEN ) +15% . Losers: Cingulate CING -28...

CING - Cingulate stock slumps ~15% on commercialization pact for ADHD drug CTx-1301

2023-03-13 09:14:08 ET Cingulate ( NASDAQ: CING ) signed a joint commercialization agreement with Indegene for its lead drug candidate CTx-1301 to treat attention deficit/hyperactivity disorder (ADHD). Cingulate said the agreement spans cross-functional services via a...

Previous 10 Next 10